# Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

Study · id `cardio:ct-nct06962098` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06962098](<https://clinicaltrials.gov/study/NCT06962098>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06962098

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 186 participants.

## Technical summary

Registry record NCT06962098. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 186 participants (planned count; ClinicalTrials.gov record NCT06962098, source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)
- Started: 2025-05-26 (actual) (ClinicalTrials.gov record NCT06962098, source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT06962098, source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT06962098, source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06962098, source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06962098-2025-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
- Acronym: PROMISS-DKD
- Condition: Diabetic Kidney Disease (DKD)
- Intervention (Drug): Isuzinaxib
- Intervention (Drug): Placebo
- Lead sponsor: Aptabio Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 52beacd42bfca174cae49e7f5d3b40d3949c9b139f7672f5818c6ac70e162abf
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
